Recombinant Human B7-H4 (C-mFc)

Description

EnkiLife provides the Recombinant Human B7-H4 (C-mFc) protein,aslo know as B7S1,B7x,Vtcn1,B7h.5,B7-H4,B7H4T-cell costimulatory molecule B7x,B7S1VCTN1,B7XPRO1291,FLJ22418,Immune costimulatory protein B7-H4,Protein B7S1,T cell costimulatory molecule B7x,V-set domain containing T cell activation inhibitor 1,V-set domain-containing T-cell activation inhibitor 1, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human B7 Homolog 4 is produced by our Mammalian expression system and the target gene encoding Phe29-Ala258 is expressed with a mouse IgG1 Fc tag at the C-terminus.Accession:Q7Z7D3. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:51.9 KDa. Background:B7 Homolog 4 (B7-H4) is glycosylated member of the B7 family of immune costimulatory proteins. Mature human B7-H4 consists of a 235 amino acid (aa) extracellular domain (ECD) with two Ig-like V-type domains, a 21 aa transmembrane segment, and a 2 aa cytoplasmic tail. It is widely expressed, including in kidney, liver, lung, pancreas, placenta, prostate, spleen, testis and thymus. B7-H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. It also involved in promoting epithelial cell transformation.